Inhibition of THC-induced effects on the central nervous system and heart rate by a novel CB1 receptor antagonist AVE1625

CB1 antagonists such as AVE1625 are potentially useful in the treatment of obesity, smoking cessation and cognitive impairment. Proof of pharmacological action of AVE1625 in the brain can be given by antagonising the effects of delta-9-tetrahydrocannabinol (THC), a CB1/CB2 agonist. Inhibition of THC-induced effects by AVE1625 was observed on Visual Analogue Scales ‘alertness’, ‘feeling high’, ‘external perception’, ‘body sway’ and ‘heart rate’. Even the lowest dose of AVE1625 20 mg inhibited most of THC-induced effects. AVE1625 did not have any effect on psychological and behavioural parameters or heart rate by itself. After THC and AVE1625 administration, changes on electroencephalography were observed. This study shows a useful method for studying the effects of CB1 antagonists. AVE1625 penetrates the brain and antagonises THC-induced effects with doses at or above 20 mg.

[1]  Patrick Dupont,et al.  [18F]MK-9470, a positron emission tomography (PET) tracer for in vivo human PET brain imaging of the cannabinoid-1 receptor , 2007, Proceedings of the National Academy of Sciences.

[2]  B. M. Wright.  A simple mechanical ataxia-meter. , 1971, The Journal of physiology.

[3]  A. Rissanen,et al.  Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study , 2005, The Lancet.

[4]  S. Heishman,et al.  Blockade of effects of smoked marijuana by the CB1-selective cannabinoid receptor antagonist SR141716. , 2001, Archives of general psychiatry.

[5]  S. Russmann,et al.  Development and pharmacokinetic characterization of pulmonal and intravenous delta-9-tetrahydrocannabinol (THC) in humans. , 2004, Journal of pharmaceutical sciences.

[6]  M. Ussher,et al.  Cannabinoid type 1 receptor antagonists (rimonabant) for smoking cessation. , 2007, The Cochrane database of systematic reviews.

[7]  Ralitza Gueorguieva,et al.  The Psychotomimetic Effects of Intravenous Delta-9-Tetrahydrocannabinol in Healthy Individuals: Implications for Psychosis , 2004, Neuropsychopharmacology.

[8]  S. Casswell.  Cannabis Intoxication: Effects of Monetary Incentive on Performance, a Controlled Investigation of Behavioural Tolerance in Moderate Users of Cannabis , 1975, Perceptual and motor skills.

[9]  A. Bond,et al.  The use of analogue scales in rating subjective feelings , 1974 .

[10]  H. Meltzer,et al.  Placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder. , 2004, The American journal of psychiatry.

[11]  S. Heishman,et al.  Single and multiple doses of rimonabant antagonize acute effects of smoked cannabis in male cannabis users , 2007, Psychopharmacology.

[12]  S. Cooper.  Endocannabinoids and food consumption: comparisons with benzodiazepine and opioid palatability-dependent appetite. , 2004, European journal of pharmacology.

[13]  R. Verpoorte,et al.  Chromatographic and Spectroscopic Data of Cannabinoids from Cannabis sativa L. , 2005 .

[14]  Ralitza Gueorguieva,et al.  Delta-9-tetrahydrocannabinol effects in schizophrenia: Implications for cognition, psychosis, and addiction , 2005, Biological Psychiatry.

[15]  Therese Garrick,et al.  Selective antagonist [3H]SR141716A binding to cannabinoid CB1 receptors is increased in the anterior cingulate cortex in schizophrenia , 2004, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[16]  M. Elsohly,et al.  Chemical constituents of marijuana: the complex mixture of natural cannabinoids. , 2005, Life sciences.

[17]  R. Murray,et al.  Cannabis use and psychiatric and cogitive disorders: the chicken or the egg? , 2007, Current opinion in psychiatry.

[18]  Y. Agid,et al.  Neurokinin B, Neurotensin, and Cannabinoid Receptor Antagonists and Parkinson Disease , 2004, Clinical neuropharmacology.

[19]  R. Schoemaker,et al.  Modelling of the concentration—effect relationship of THC on central nervous system parameters and heart rate — insight into its mechanisms of action and a tool for clinical research and development of cannabinoids , 2008, Journal of psychopharmacology.

[20]  Robert Verpoorte,et al.  Preparative Isolation of Cannabinoids from Cannabis sativa by Centrifugal Partition Chromatography , 2004 .

[21]  A. Rissanen,et al.  Effect of rimonabant on weight reduction and cardiovascular risk , 2005, The Lancet.

[22]  R. Pertwee,et al.  Evidence for the presence of CB1 cannabinoid receptors on peripheral neurones and for the existence of neuronal non-CB1 cannabinoid receptors. , 1999, Life sciences.

[23]  Y. Choi,et al.  NMR assignments of the major cannabinoids and cannabiflavonoids isolated from flowers of Cannabis sativa. , 2004, Phytochemical analysis : PCA.

[24]  H. Norris.  The action of sedatives on brain stem oculomotor systems in man. , 1971, Neuropharmacology.

[25]  Lineke Zuurman,et al.  Evaluation of a vaporizing device (Volcano) for the pulmonary administration of tetrahydrocannabinol. , 2006, Journal of pharmaceutical sciences.

[26]  Wright Bm.  A simple mechanical ataxia-meter. , 1971 .

[27]  A. Bowdle,et al.  Psychedelic Effects of Ketamine in Healthy Volunteers: Relationship to Steady‐state Plasma Concentrations , 1998, Anesthesiology.

[28]  B. Ferrer,et al.  Cannabinoid CB1 antagonists possess antiparkinsonian efficacy only in rats with very severe nigral lesion in experimental parkinsonism , 2005, Neurobiology of Disease.